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Progesterone and estrogen are two steroid hormones whose exposure may decrease the risk and delay 
the onset of ischemic stroke. The main objective of this study was to determine the plasma level of 
progesterone, estrogen and ratio of progesterone/estrogen in ischemic stroke patients. The plasma 
levels of progesterone, estrogen and ratio of progesterone/estrogen in 30 patients (15 men and 15 
women) with acute ischemic stroke was determined within 12 h of the onset of the attack as well as in 
30 control subjects (15 men and 15 women) of comparable age. There were significant differences 
between the progesterone and ratio of progesterone/estrogen of stroke and control group (p = 0.022 
and p = 0.001, respectively). Compared with control, stroke patients had lower levels of progesterone 
and ratio of progesterone/estrogen. There were not significant differences between levels of estradiol in 
stroke and control groups. The results showed ischemic stroke is accompanied by reduction of 
progesterone and ratio of progesterone/estradiol. These reductions might be involved in the decreased 
protection of brain to ischemic injury.  
 





Progesterone and estrogen are gonadal hormones that 
are present in the blood circulation of both males and 
females and whose exposure may decrease the risk and 
delay the onset of ischemic stroke (Singh, 2006; Stein 
and Hoffman, 2003). Neuroprotective effects against 
cerebral ischemia of both hormones have been shown 
(Stein, 2008; Alonso et al., 2006). Study on animal and 
tissue culture models suggest that the loss of both 
estrogens and progestins makes the brain more 
vulnerable to acute insults and chronic neurodege-
nerative diseases (Simpkins et al., 2005). A number of 
studies have investigated the roles of progesterone and 
estrogen in stroke in humans, focusing primarily on 
incidence, sex, age of first stroke and outcome (Roof and 
Hall, 2000; Abbott et al., 2007; Stein, 2007). But, most 
attention has focused only on progesterone or estrogen 
alone and only a few instances have concomitantly eval-
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patients (Toung et al., 2004; Alkeyed et al., 2000). The 
questions are whether plasma level of progesterone and 
estrogen or ratio of progesterone to estrogen is different 
in ischemia stroke patients compare to controls. To the 
best of the present knowledge, no information is available 
about change of progesterone to estrogen ratio from 
ischemia stroke patients. The main objective of this study 
was to determine the plasma level of progesterone, estro-




MATERIALS AND METHODS 
 
Thirty patients older than 61 years with acute ischemic stroke 
admitted within 12 h from the onset of symptoms to the emergency 
room of the Sina University Hospital, Hamadan, Iran, were 
consecutively enrolled. On admission, demographic characteristics, 
detailed history and clinical information for stroke risk factors were 
recorded. Laboratory tests (blood cell count, biochemical studies 
including lipid profiles and serum electrolytes, urinalysis), chest 
radiography and electrocardiography were performed in all patients. 
All patients were investigated to clarify etiologic factors for stroke. 
Computed tomography (CT) of the brain was performed in all 
patients. Subjects with hemorrhagic stroke, other  neurological  disease  




Table 1. Plasma levels (mean ± SD) of progesterone, estradiol and ratio of 
progesterone/estradiol of stroke and control groups. 
 
Parameters Stroke (n = 30) Control (n = 30) P value 
Progesterone (nmol/l) 4.1 ± 2 5.08 ± 1 0.022 
Estradiol(nmol/l) 0.23 ± 0.07 0.24 ± 0.03 0.54 




and patients with body temperature higher than 37.5 °C, inflam-
matory process, diabetes mellitus, liver disease and renal impair-
ment were excluded from the study. None of the stroke subjects 
was undergoing hormone replacement treatments. The inclusion 
criteria for controls were age  59 years, outpatient healthy subjects 
and nonsmokers. The exclusion criteria for controls were inflame-
mation, infection, presence of neurological dysfunction and history 
of myocardial infarction. The severity of stroke at admission was 
measured by Canadian Neurological Scale (CNS) (Cote et al., 
1989). Heparinized venous blood samples were taken and plasma 
was separated and stored at - 70°C. Results from the patient group 
were compared with those obtained from 30 healthy subjects of 
comparable age and gender. None of the control subjects was 
undergoing pharmacological treatments. Written informed consents 
were obtained from all participants or their relatives, according to 




Progesterone and estradiol assay 
 
Plasma progesterone and 17- estradiol was measured using a 
quantitative competitive immunoassay kit (DRG Instruments 
Company, Germany). The level of progesterone and 17- estradiol 





Results were expressed as means ± SD. Kolmogorov-Smirnov 
goodness of test was used for normality distribution of proges-
terone, estradiol and progesterone/estradiol ratio and CNS score. 
Student’s t test was used to detect differences of progesterone, 
estradiol, progesterone/estradiol ratio and CNS score between 
males and females from stroke and control groups. A value of p < 





The study population consisted of 60 subjects: 30 
patients with acute ischemic stroke admitted within 12 h 
from onset (15 men and 15 women, aged 70.6 ± 8.3 and 
70.4 ±10.8 years, respectively) and 30 controls (15 men 
and 15 women, aged 68.5 ± 8.4 and 66.2 ± 7.6 years, 
respectively). The mean CNS score in all patients of 
stroke group was 6.35 ± 1.5. The mean CNS score in 
men and women of stroke group was 6.8 ± 1.1 and 5.6 ± 
1.35, respectively, and the difference was significant (p < 
0.05). Progesterone and estradiol was assayed in 
duplicate for each plasma sample. The mean values of 
the progesterone and estradiol and progesterone/ 
estradiol ratio in the stroke and control groups are shown 
in Table 1. There were significant differences between 
level of progesterone and progesterone/estradiol ratio in 
stroke compared to control group (p = 0.022 and p = 
0.001, respectively). The mean values of the proges-
terone and estradiol and progesterone/estradiol ratio in 
the males and females of stroke and control groups are 
shown in Table 1. There were not significant differences 
between the level of progesterone, estradiol and proges-






In the present study, the plasma levels of progesterone, 
estradiol and progesterone/estradiol ratio in the patients 
with ischemic stroke and healthy subjects were deter-
mined. The study showed that there were significant 
differences in levels of progesterone and progesterone/ 
estradiol ratio in stroke patients compared to control 
group. Some information has been obtained regarding the 
mechanism underlying progesterone’s neuroprotective 
effects (Singh, 2006; Stein et and Hoffman, 2003; 
Simpkins et al., 2005). The neuroprotection was provided 
by protecting the blood-brain barrier, reduction of cerebral 
edema, reduction of inflammatory cytokines, limiting 
cellular necrosis and apoptosis and antioxidant effects 
(Singh, 2006; Stein, 2008; Simpkins et al., 2005; Alkeyed 
et al., 2000; Vaisi-Raygani et al., 2009; Kharrazi et al., 
2008).  
The findings showed that endogenous progesterone 
was decreased in stroke compared to control group. The 
decrease of progesterone in stroke group may be partly 
due to reduction of synthesis or increase of metabolism 
to other compounds. A number of researchers studied 
the progesterone effect on reduction of the cones-
quences of cerebral ischemia. Administration of proges-
terone resulted in a significantly smaller cortical infarction 
volume, less weight loss and better neuralgic outcome 
(Stein, 2008; Alkeyed et al., 2000). Jiang et al. (1996) 
showed that the administration of progesterone before 
middle cerebral artery occlusion caused a reduction in 
cerebral infarction. In addition, administration of proges-
terone after the ischemic event can protect brain against 
injury (Morali et al., 2005; Kumon et al., 2000). Although 
in most studies, the effect of exogenous progesterone 
has been studied and less is known about the relation-
ship of stroke with endogenous progesterone.  
In the present study, the ratio of progesterone/estradiol 
was lower in  stroke  compared  to  control  group.  Some  




evidence suggested that the greater neuroprotection 
attributed in females compared with males is likely due to 
effects of circulating progesterone and estrogen(Stein 
and Hoffman, 2003; Simpkins et al., 2005; Roof and Hall, 
2000; Toung et al., 2004). In fact, exogenous admini-
stration of both hormones has been shown to improve 
outcome after cerebral ischemia in experimental models 
(Roof and Hall, 2000). It is not clear whether endogenous 
progesterone and estrogen insert neuroprotection effect 
in company with the other or not. In the most research, 
progesterone or estrogen is studied alone and the possi-
ble link of these hormones against stroke was not 
noticed. Since, in stroke group, the greater p-value for 
ratio of progesterone/estradiol (p = 0.001) compared to 
progesterone (p = 0.022) was found, this finding suggest 
that the ratio of progesterone/estradiol is a more impor-
tant factor compared to progesterone or estradiol alone. 
In conclusion, the present results showed ischemic 
stroke is accompanied by reduction of progesterone and 
ratio of progesterone/estradiol. These reductions might 
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